From Alder Sets Stage for Showdown With Roche, With “Fast Follower” Antibody Drug Strategy:

alderlogo
alderlogo—

Alder Biopharmaceuticals is developing antibody drugs for rheumatoid arthritis and cancer

    

Xconomy’s Most Popular

  1. Biotech IPOs Start to Show Some Modest Signs of Life
  2. ASCO Preview: Eight Cancer Drugs to Watch at the Big Show
  3. Hey, Silicon Valley: Wake Up and Smell the Robots
  4. Announcing Xconomy’s Napa Summit: Keeping America Growing
  5. From MIT Entrepreneur to Tea Party Leader: The Thomas Massie Story

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Mozy
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.